Cerus, NMDP initiate Phase IB clinical trial of cellular therapy to improve stem cell transplants.Cerus Corporation, Concord, CA, announced it has initiated a Phase IB clinical trial for its allogeneic allogeneic /al·lo·ge·ne·ic/ (-je-ne´ik) 1. having cell types that are antigenically distinct. 2. in transplantation biology, denoting individuals (or tissues) that are of the same species but antigenically cellular immune therapy (ACIT ACIT Academic Consortium on International Trade ACIT Al Ahram Center for Interpreting & Translation (Cairo, Egypt) ACIT Association of Christians in Information Technology (UK) ) in collaboration with the National Marrow Donor Program The National Marrow Donor Program (NMDP) is a nonprofit organization based in Minneapolis, Minnesota, that operates the federally funded registry of volunteer hematopoietic cell donors in the United States. These potential donors, numbering more than 6. , Minneapolis, MN. The company says the ACIT is being developed to improve stem cell transplant outcomes in patients with hematologic malignancies including leukemia and lymphoma. The trial is a multi-center, investigator-sponsored study, which will evaluate 3 different doses. Cerus says a maximum of 42 patients with hematologic malignancies will be enrolled in the study and will receive Helinx-treated T-cells as an adjunct to unrelated donor stem cell transplants. The company says the study is designed to demonstrate the safety of a combination treatment regimen consisting of stem cells and Helinx-treated T-cells in patients with leukemia and lymphoma. Primary end points include the incidence of acute graft-versus-host disease and the incidence of transplant engraftment engraftment /en·graft·ment/ (en-graft´ment) incorporation of grafted tissue into the body of the host. Engraftment The process of transplanted stem cells reproducing new cells. . Contact: Cerus Web site: www.cerus.com; NMDP NMDP National Marrow Donor Program NMDP National Missile Defense Program - (800) 627-7692, Web site: www.marrow.org. |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion